Skip to main content
. 2015 Jan 20;125(2):715–726. doi: 10.1172/JCI77632

Figure 2. AMPK agonist AICAR exerts renoprotection in mice with AKI by increasing SIRT3.

Figure 2

(A) Western blot and densitometric analysis of pAMPKα and total AMPKα in the renal tissue of control and cisplatin-treated mice given saline or AICAR at 4 days. *P < 0.05, ANOVA corrected with Bonferroni coefficient. n = 5 control mice; n = 7 cisplatin mice+saline; n = 6 cisplatin mice+AICAR. (B) Renal function in control mice and cisplatin-treated mice receiving saline or AICAR at 4 days. ***P < 0.001, ANOVA corrected with Bonferroni coefficient. n = 7 control mice; n = 8 cisplatin mice+saline; n = 8 cisplatin mice+AICAR. (C) Effect of AICAR treatment on renal histological changes at 4 days evaluated as number of cast and necrotic tubules per HPF. ***P < 0.001, ANOVA corrected with Bonferroni coefficient. n = 6 mice per group. (D) Renal expression of Nampt, Pgc1a, and Sirt3 transcripts studied by real-time PCR in control and cisplatin-treated mice given saline or AICAR at 4 days. *P < 0.05, **P < 0.01, and ***P < 0.001, ANOVA corrected with Bonferroni coefficient. n = 6 mice per group. (E) Representative images of SIRT3 protein staining (green) in proximal tubules of control and cisplatin-treated mice given saline or AICAR at 4 days. Scale bars: 10 μm.